691 related articles for article (PubMed ID: 29905825)
1. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
Capozzi ME; DiMarchi RD; Tschöp MH; Finan B; Campbell JE
Endocr Rev; 2018 Oct; 39(5):719-738. PubMed ID: 29905825
[TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
3. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
5. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
[TBL] [Abstract][Full Text] [Related]
7. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
8. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
9. Incretin therapy for diabetes mellitus type 2.
Holst JJ
Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):2-10. PubMed ID: 31815785
[TBL] [Abstract][Full Text] [Related]
10. Incretin hormone mimetics and analogues in diabetes therapeutics.
Green BD; Flatt PR
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists.
Jiménez-Martí E; Hurtado-Genovés G; Aguilar-Ballester M; Martínez-Hervás S; González-Navarro H
Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145148
[TBL] [Abstract][Full Text] [Related]
12. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
Spasov AA; Chepljaeva NI
Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
[TBL] [Abstract][Full Text] [Related]
13. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
[TBL] [Abstract][Full Text] [Related]
14. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ; Radermecker RP; Paquot N
Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
[TBL] [Abstract][Full Text] [Related]
15. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
16. The incretin/glucagon system as a target for pharmacotherapy of obesity.
Del Prato S; Gallwitz B; Holst JJ; Meier JJ
Obes Rev; 2022 Feb; 23(2):e13372. PubMed ID: 34713962
[TBL] [Abstract][Full Text] [Related]
17. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
[TBL] [Abstract][Full Text] [Related]
18. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms RJ; Coghlan MP; Sloop KW
Trends Endocrinol Metab; 2020 Jun; 31(6):410-421. PubMed ID: 32396843
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio LL; Drucker DJ
Mol Metab; 2021 Apr; 46():101090. PubMed ID: 32987188
[TBL] [Abstract][Full Text] [Related]
20. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
